logo

CLBT

Cellebrite DI·NASDAQ
--
--(--)
--
--(--)
8.73 / 10
Outperform

Fundamental breakdown reveals outstanding profile (8.7/10). Supportive elements: Operating cycle and Interest coverage ratio (EBIT / Interest expense) (%), with caution warranted for Asset-MV and Revenue-MV. This suggests excellent positioning.

Fundamental(8.73)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-1.38
Score1/3
Weight-5.69%
1M Return-1.14%
Asset-liability ratio (%)
Value46.34
Score0/3
Weight-4.52%
1M Return-0.86%
Annualized return on equity (%)
Value19.42
Score2/3
Weight25.35%
1M Return4.01%
Operating cycle
Value115.40
Score3/3
Weight36.71%
1M Return6.52%
Profit-MV
Value-0.47
Score0/3
Weight-8.23%
1M Return-1.48%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score3/3
Weight16.95%
1M Return2.95%
Asset-MV
Value-0.50
Score0/3
Weight-22.67%
1M Return-5.22%
ROE (%)
Value14.56
Score2/3
Weight25.35%
1M Return4.01%
Inventory turnover days
Value42.79
Score2/3
Weight22.50%
1M Return3.86%
Cash-MV
Value-1.24
Score2/3
Weight14.26%
1M Return2.31%
Is CLBT undervalued or overvalued?
  • CLBT scores 8.73/10 on fundamentals and holds a Discounted valuation at present. Backed by its 14.56% ROE, 16.74% net margin, 45.38 P/E ratio, 7.74 P/B ratio, and 124.68% earnings growth, these metrics solidify its Outperform investment rating.